論文

査読有り 筆頭著者 国際誌
2018年6月

Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants.

International journal of oncology
  • Shiho Asaka
  • ,
  • Akihiko Yoshizawa
  • ,
  • Kazusa Saito
  • ,
  • Yukihiro Kobayashi
  • ,
  • Hiroshi Yamamoto
  • ,
  • Tatsuya Negishi
  • ,
  • Rie Nakata
  • ,
  • Kazuyuki Matsuda
  • ,
  • Akemi Yamaguchi
  • ,
  • Takayuki Honda

52
6
開始ページ
2110
終了ページ
2118
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3892/ijo.2018.4334

Epidermal growth factor receptor (EGFR) mutations are associated with responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). Our previous study revealed a rapid point-of-care system for detecting EGFR mutations. This system analyzes cell pellets from cytology specimens using droplet-polymerase chain reaction (d-PCR), and has a reaction time of 10 min. The present study aimed to validate the performance of the EGFR d-PCR assay using cell-free DNA (cfDNA) from supernatants obtained from cytology specimens. Assay results from cfDNA supernatant analyses were compared with those from cell pellets for 90 patients who were clinically diagnosed with, or suspected of having, lung cancer (80 bronchial lavage fluid samples, nine pleural effusion samples and one spinal fluid sample). EGFR mutations were identified in 12 and 15 cases using cfDNA supernatants and cell pellets, respectively. The concordance rates between cfDNA-supernatant and cell‑pellet assay results were 96.7% [kappa coefficient (K)=0.87], 98.9% (K=0.94), 98.9% (K=0.79) and 98.9% (K=0.79) for total EGFR mutations, L858R, E746_A750del and T790M, respectively. All 15 patients with EGFR mutation-positive results, as determined by EGFR d-PCR assay using cfDNA supernatants or cell pellets, also displayed positive results by conventional EGFR assays using tumor tissue or cytology specimens. Notably, EGFR mutations were even detected in five cfDNA supernatants for which the cytological diagnoses of the corresponding cell pellets were 'suspicious for malignancy', 'atypical' or 'negative for malignancy.' In conclusion, this rapid point-of-care system may be considered a promising novel screening method that may enable patients with NSCLC to receive EGFR-TKI therapy more rapidly, whilst also reserving cell pellets for additional morphological and molecular analyses.

Web of Science ® 被引用回数 : 11

リンク情報
DOI
https://doi.org/10.3892/ijo.2018.4334
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29620164
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000432241200032&DestApp=WOS_CPL
ID情報
  • DOI : 10.3892/ijo.2018.4334
  • ORCIDのPut Code : 50664268
  • PubMed ID : 29620164
  • Web of Science ID : WOS:000432241200032

エクスポート
BibTeX RIS